A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope
Kidney International · 2024-11 · 106 (5) · 972-984
DOI: 10.1016/j.kint.2024.08.019 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Kidney International, 2024-11. Verfasst von Satoshi Miyamoto und 27 weiteren Autor:innen. Beteiligte Einrichtung: Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan; Department of Internal Medicine, Innoshima General Hospital, On…. Hauptthemen laut MEDLINE: Canagliflozin, Glomerular Filtration Rate, Albuminuria, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mitsubishi Tanabe Pharma Corporation.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan; Department of Internal Medicine, Innoshima General Hospital, Onomichi, Japan. Electronic address: s1miyamoto@okayama-u.ac.jp.
- Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Electronic address: h.j.lambers.heerspink@umcg.nl.
- Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
- Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
- Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.
- Suzuki Diadetes Clinic, Atsugi, Japan.
Förderung
- Mitsubishi Tanabe Pharma Corporation
Zitieren
APA
Miyamoto, S., Heerspink, H. J. L., de Zeeuw, D., Sakamoto, K., Yoshida, M., Toyoda, M., Suzuki, D., Hatanaka, T., Nakamura, T., Kamei, S., Murao, S., Hida, K., Ando, S., Akai, H., Takahashi, Y., Kitada, M., Sugano, H., Nunoue, T., Nakamura, A., …, & CANPIONE study Investigators (2024). A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope. Kidney International. https://doi.org/10.1016/j.kint.2024.08.019
Vancouver
Miyamoto S, Heerspink HJL, de Zeeuw D, Sakamoto K, Yoshida M, Toyoda M, et al. A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope. Kidney International. 2024. doi:10.1016/j.kint.2024.08.019
BibTeX
@article{Miyamoto2024,
author = {Miyamoto, Satoshi and Heerspink, Hiddo J L and de Zeeuw, Dick and Sakamoto, Kota and Yoshida, Michihiro and Toyoda, Masao and Suzuki, Daisuke and Hatanaka, Takashi and Nakamura, Tohru and Kamei, Shinji and Murao, Satoshi and Hida, Kazuyuki and Ando, Shinichiro and Akai, Hiroaki and Takahashi, Yasushi and Kitada, Munehiro and Sugano, Hisashi and Nunoue, Tomokazu and Nakamura, Akihiko and Sasaki, Motofumi and Nakatou, Tatsuaki and Fujimoto, Kei and Kawanami, Daiji and Wada, Takashi and Miyatake, Nobuyuki and Kuramoto, Hiromi and Shikata, Kenichi and CANPIONE study Investigators, CANPIONE study Investigators},
title = {A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope},
journal = {Kidney International},
year = {2024},
doi = {10.1016/j.kint.2024.08.019}
}
EUVIMED